Log In
Print
BCIQ
Print
Print this Print this
 

TRV734

  Manage Alerts
Collapse Summary General Information
Company Trevena Inc.
DescriptionG protein-biased mu opioid receptor (OPRM1; MOR) ligand
Molecular Target Mu opioid receptor (OPRM1) (MOR)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationPain
Indication DetailsTreat moderate to severe pain
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today